Moderna Inc. (MRNA:NSD) Analysts rate as a Hold, $188 target

STA Research
by: STA Research

Based on the Moderna Inc stock forecasts from 11 analysts, the average analyst target price for Moderna Inc is USD 188.39 over the next 12 months. Moderna Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Moderna Inc is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Moderna Inc’s stock price was USD 145.34. Moderna Inc’s stock price has changed by +0.01% over the past week, +10.94% over the past month and -31.77% over the last year.

SVB Leerink maintained the Underperform rating on the stock, and cut the target to $70 from $80.

Biotechnology company Moderna, Inc. specialises in the research, development, and commercialization of messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases in the United States, Europe, and internationally.

The business formerly went by the name Moderna Therapeutics, Inc., but in August 2018 it transitioned to operating under the name Moderna, Inc. The company that is now known as Moderna, Inc. was established in 2010 and maintains its headquarters in Cambridge, Massachusetts.

 

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

 

What we don’t like:

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peer’s median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering buying.

 

Leave a Reply

Your email address will not be published.